| 101 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Finland |
40 |
| 102 |
Bone Marrow Family |
Allogeneic |
T-Cell Prolymphocytic Leukemia |
Hematology |
2026 |
Standard Therapy |
Norway |
64 |
| 103 |
Bone Marrow Family |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
Spain |
47 |
| 104 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Poland |
66 |
| 105 |
Bone Marrow Family |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Czechia |
68 |
| 106 |
Bone Marrow Family |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Poland |
26 |
| 107 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Germany |
3 |
| 108 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Hungary |
62 |
| 109 |
Bone Marrow |
Allogeneic |
Fanconi Anemia |
Hematology |
2026 |
Standard Therapy |
Austria |
7 |
| 110 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Belgium |
12 |
| 111 |
Bone Marrow |
Allogeneic |
Combined Immunodeficiency |
Hematology |
2026 |
Standard Therapy |
Belgia |
3 |
| 112 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Italy |
60 |
| 113 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
Italy |
7 |
| 114 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
Italy |
4 |
| 115 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Germany |
8 |
| 116 |
Bone Marrow |
Allogeneic |
Other Immune System |
Hematology |
2026 |
Standard Therapy |
USA |
5 |
| 117 |
Bone Marrow |
Allogeneic |
Adrenoleukodystrophy (X-ALD) |
Hematology |
2026 |
Standard Therapy |
Czechia |
5 |
| 118 |
Bone Marrow |
Allogeneic |
Wiskott-Aldrich Syndrome |
Hematology |
2026 |
Standard Therapy |
Germany |
19 |
| 119 |
Bone Marrow |
Allogeneic |
Wiskott-Aldrich Syndrome |
Hematology |
2026 |
Standard Therapy |
USA |
11 |
| 120 |
Bone Marrow |
Allogeneic |
Serum Amyloid A (SAA) |
Hematology |
2026 |
Standard Therapy |
Austria |
16 |
| 121 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
France |
32 |
| 122 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
Germany |
16 |
| 123 |
Bone Marrow |
Allogeneic |
Other Malignancy |
Hematology |
2026 |
Standard Therapy |
France |
5 |
| 124 |
Bone Marrow |
Allogeneic |
Mixed type Leukemia |
Hematology |
2026 |
Standard Therapy |
Poland |
1 |
| 125 |
Bone Marrow |
Allogeneic |
OIID, Chronic Granulomatous Disease CGD |
Hematology |
2026 |
Standard Therapy |
Germany |
2 |
| 126 |
Bone Marrow |
Allogeneic |
GATA2 deficiency |
Hematology |
2026 |
Standard Therapy |
Belgium |
12 |
| 127 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Italy |
48 |
| 128 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Poland |
47 |
| 129 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
United Kingdom |
80 |
| 130 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
United Kingdom |
15 |
| 131 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia / AA Amyloidosis |
Hematology |
2026 |
Standard Therapy |
United Kingdom |
24 |
| 132 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Turkey |
8 |
| 133 |
Bone Marrow |
Allogeneic |
SCID Severe Combined Immunodeficiency |
Hematology |
2026 |
Standard Therapy |
Poland |
1 |
| 134 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
Germany |
58 |
| 135 |
Bone Marrow |
Allogeneic |
Pure Red Cell Aplasia |
Hematology |
2026 |
Standard Therapy |
USA |
29 |
| 136 |
Bone Marrow |
Allogeneic |
Combined Immunodeficiency |
Hematology |
2026 |
Standard Therapy |
USA |
19 |
| 137 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
France |
21 |
| 138 |
Bone Marrow |
Allogeneic |
B-thalassemia |
Hematology |
2026 |
Standard Therapy |
Netherlands |
15 |
| 139 |
Bone Marrow |
Allogeneic |
Very Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
Slovakia |
31 |
| 140 |
Bone Marrow |
Allogeneic |
Hemophagocytic Lymphohistiocytosis |
Hematology |
2026 |
Standard Therapy |
Austria |
3 |
| 141 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Poland |
12 |
| 142 |
Bone Marrow |
Allogeneic |
Diamond Blackfan Anemia |
Hematology |
2026 |
Standard Therapy |
Slovakia |
9 |
| 143 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Brazil |
62 |
| 144 |
Bone Marrow |
Allogeneic |
Griscelli syndrome type 2 |
Hematology |
2026 |
Standard Therapy |
Canada |
39 |
| 145 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
France |
47 |
| 146 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
USA |
21 |
| 147 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
Hungary |
10 |
| 148 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Poland |
70 |
| 149 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
USA |
6 |
| 150 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia CR2 |
Hematology |
2026 |
Standard Therapy |
Spain |
9 |
| 151 |
Bone Marrow |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
France |
7 |
| 152 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Hungary |
23 |
| 153 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
USA |
8 |
| 154 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
USA |
20 |
| 155 |
Bone Marrow |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Poland |
1 |
| 156 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
USA |
13 |
| 157 |
Bone Marrow |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2026 |
Standard Therapy |
USA |
2 months |
| 158 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
Italy |
3 |
| 159 |
Bone Marrow |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2026 |
Standard Therapy |
USA |
26 |
| 160 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Hungary |
9 |
| 161 |
Bone Marrow |
Allogeneic |
Chronic Myelomonocytic Leukemia |
Hematology |
2026 |
Standard Therapy |
Spain |
61 |
| 162 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Germany |
2 |
| 163 |
Bone Marrow |
Allogeneic |
Other Leukaemia |
Hematology |
2026 |
Standard Therapy |
France |
1 |
| 164 |
Bone Marrow |
Allogeneic |
– |
Hematology |
2026 |
Standard Therapy |
Germany |
16 |
| 165 |
Bone Marrow |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2026 |
Standard Therapy |
Belarus |
2 |
| 166 |
Bone Marrow |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
United Kingdom |
11 |
| 167 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard Therapy |
Germany |
61 |
| 168 |
Apheresis |
Autologous |
Plasmablastic Lymphoma |
Hematology |
2026 |
Standard Therapy |
Germany |
69 |
| 169 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard Therapy |
Germany |
60 |
| 170 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard Therapy |
Portugal |
54 |
| 171 |
Apheresis |
Autologous |
Multiple Myeloma |
Hematology |
2026 |
Standard Therapy |
Portugal |
67 |
| 172 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
France |
68 |
| 173 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Canada |
69 |
| 174 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Italy |
66 |
| 175 |
Apheresis |
Allogeneic |
Fanconi Anemia |
Hematology |
2026 |
Standard Therapy |
Germany |
4 |
| 176 |
Apheresis |
Allogeneic |
Leukemia T-PLL |
Hematology |
2026 |
Standard Therapy |
Norway |
64 |
| 177 |
Apheresis |
Allogeneic |
T-cell NHL Non-Hodgkin Lymphoma |
Hematology |
2026 |
Standard Therapy |
Germany |
46 |
| 178 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Germany |
60 |
| 179 |
Apheresis |
Allogeneic |
MM, Myeloma Multiplex |
Hematology |
2026 |
Standard Therapy |
Poland |
48 |
| 180 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Norway |
29 |
| 181 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2026 |
Standard Therapy |
USA |
27 |
| 182 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Austria |
34 |
| 183 |
Apheresis |
Allogeneic |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) |
Hematology |
2026 |
Standard Therapy |
Poland |
55 |
| 184 |
Apheresis |
Allogeneic |
Thalassemia Major |
Hematology |
2026 |
Standard Therapy |
Turkey |
11 |
| 185 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Norway |
59 |
| 186 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
USA |
75 |
| 187 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Hungary |
62 |
| 188 |
Apheresis |
Allogeneic |
2nd Myelodysplastic Syndrome |
Hematology |
2026 |
Standard Therapy |
Netherlands |
67 |
| 189 |
Apheresis |
Allogeneic |
Acute Myelomonocytic Leukemia (AMML) |
Hematology |
2026 |
Standard Therapy |
Ukraine |
44 |
| 190 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Portugal |
59 |
| 191 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
Germany |
54 |
| 192 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
France |
67 |
| 193 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
Spain |
47 |
| 194 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
Hungary |
42 |
| 195 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Hungary |
67 |
| 196 |
Apheresis |
Allogeneic |
Prolymphocytic Leukemia |
Hematology |
2026 |
Standard Therapy |
USA |
66 |
| 197 |
Apheresis |
Allogeneic |
Other Myelofibrosis/Myelosclerosis |
Hematology |
2026 |
Standard Therapy |
USA |
59 |
| 198 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2026 |
Standard Therapy |
USA |
52 |
| 199 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Australia |
57 |
| 200 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2026 |
Standard Therapy |
Australia |
56 |